Skip to main content
Close
Home
Society of Hospital Medicine
Presented by Society of Hospital Medicine
Home
Twitter Facebook LinkedIn Instagram YouTube Hospital Medicine Exchange Email RSS Feed

M. Alexander Otto

M. Alexander Otto began his reporting career early in 1999 covering the pharmaceutical industry for a national pharmacists' magazine and freelancing for the Washington Post and other newspapers. He then joined BNA, now part of Bloomberg News, covering health law and the protection of people and animals in medical research. Alex next worked for the McClatchy Company. Based on his work, Alex won a year-long Knight Science Journalism Fellowship to MIT in 2008-2009. He joined the company shortly thereafter. Alex has a newspaper journalism degree from Syracuse (N.Y.) University and a master's degree in medical science -- a physician assistant degree -- from George Washington University. Alex is based in Seattle.

News

DLBCL: PFS but no OS benefit with polatuzumab-vedotin add-on

Author:
M. Alexander Otto
Publish date: December 17, 2021

Pending additional follow-up for overall survival, is the extra cost worth it?

  • Read More

News

ASH studies look at racial disparities in ALL care, outcomes

Author:
M. Alexander Otto
Publish date: December 15, 2021

Findings of two studies on U.S. blood cancer care suggest that “structural racism” may play a role in worse outcomes among young Hispanic and...

  • Read More

News

Talk early to patients with high-risk AML about end-of-life decisions

Author:
M. Alexander Otto
Publish date: December 12, 2021

With nearly 40% of AML patients unable to take part in their own final code discussions, families struggle to guess what their loved ones would...

  • Read More

News

Myeloid patients respond robustly to Moderna COVID vaccine

Author:
M. Alexander Otto
Publish date: December 12, 2021

Among 46 patients, nearly all seroconverted after second shot.

  • Read More

News

FDA approves new interferon for polycythemia vera

Author:
M. Alexander Otto
Publish date: November 18, 2021

A longer half-life means dosing every 2 weeks, instead of weekly.

  • Read More

News

Tolerability doesn’t explain why kids do better than adults on ALL regimens

Author:
M. Alexander Otto
Publish date: November 8, 2021

Differences in tumor biology seem to be at play.

  • Read More

News

Genes related to osteosarcoma survival identified

Author:
M. Alexander Otto
Publish date: October 5, 2021

They predict survival and are also potential therapy targets.

  • Read More

News

Better survival with extended letrozole in early-stage breast cancer

Author:
M. Alexander Otto
Publish date: September 29, 2021

Guidelines for duration of endocrine therapy ‘should be updated.’

  • Read More

News

Twelve-month overall survival benefit with ribociclib for metastatic breast cancer

Author:
M. Alexander Otto
Publish date: September 21, 2021

It’s the first phase 3 trial to report a median overall survival beyond 5 years in advanced breast cancer.

  • Read More

News

Durvalumab combos beat monotherapy for unresectable stage 3 NSCLC

Author:
M. Alexander Otto
Publish date: September 20, 2021

Combination treatment has better progression free survival with a similar safety profile.

  • Read More

News

Mediastinal relapse risk lower with PORT, but no survival benefit

Author:
M. Alexander Otto
Publish date: September 20, 2021

Post-op radiation may help patients with high mediastinal burdens.

  • Read More

News

COVID is especially dangerous for mesothelioma

Author:
M. Alexander Otto
Publish date: September 15, 2021

Case review demonstrates a mortality rate of 57%.

  • Read More

News

Unequal resource distribution underlies lung cancer disparities

Author:
M. Alexander Otto
Publish date: September 10, 2021

“We have to focus on the areas where we are most likely to be successful.”

  • Read More

News

Finding the most bang for the buck with adjuvant atezolizumab for NSCLC

Author:
M. Alexander Otto
Publish date: September 10, 2021

Lack of benefit with pneumonectomy, cisplatin-gemcitabine needs further investigation.

  • Read More

News

Study calls higher surgery costs at NCI centers into question

Author:
M. Alexander Otto
Publish date: September 1, 2021

When is the higher cost of cancer surgery at NCI centers worth it?

  • Read More

Pages

  • « first
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • last »
An Official Publication of the Society of Hospital Medicine

Society of Hospital Medicine
Twitter Facebook LinkedIn Instagram YouTube Hospital Medicine Exchange Email RSS Feed

Copyright  © 2022 Frontline Medical Communications Inc., Newark, NJ, USA. All rights reserved. Unauthorized use prohibited. The information provided is for educational purposes only. Use of this Web site is subject to the medical disclaimer.

Menu Close